Investing.com - Durect (NASDAQ: DRRX) reported fourth quarter EPS of $-0.5200, $0.48 worse than the analyst estimate of $-0.0400. Revenue for the quarter came in at $2.1M versus...
Investing.com - Durect (NASDAQ:DRRX) reported on Monday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Durect announced...
DURECT Corp (DRRX) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.1 million versus the consensus estimate of $3.84...
DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of acute organ injury and chronic...
DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute organ injury and chronic liver...
Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Oil & Gas, Basic Materials and Industrials sectors led shares lower. At the close in NYSE, the...
DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David...